- Report
- October 2024
- 195 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- April 2025
- 181 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- February 2025
- 315 Pages
Global
From €4368EUR$4,799USD£3,710GBP
- Report
- January 2025
- 363 Pages
Global
From €4368EUR$4,799USD£3,710GBP
- Report
- December 2024
- 598 Pages
Global
From €4368EUR$4,799USD£3,710GBP
- Report
- March 2025
- 1048 Pages
Global
From €4368EUR$4,799USD£3,710GBP
- Report
- October 2024
- 182 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- March 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- March 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 179 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- September 2024
- 150 Pages
Global
From €4414EUR$4,850USD£3,749GBP
- Report
- May 2024
- 138 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 182 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Drug Pipelines
- April 2025
- 280 Pages
Global
From €2731EUR$3,000USD£2,319GBP
- Clinical Trials
- April 2025
- 450 Pages
Global
From €4551EUR$5,000USD£3,865GBP
- Drug Pipelines
- April 2025
- 40 Pages
Global
From €1138EUR$1,250USD£966GBP
- Report
- August 2024
- 150 Pages
Global
From €2538EUR$2,789USD£2,156GBP

Engineered T Cells are a type of biotechnology that involves the genetic engineering of a patient's own T cells to create a personalized therapy for the treatment of cancer and other diseases. This technology is based on the idea of using the body's own immune system to fight disease. The engineered T cells are modified to recognize and attack cancer cells, while leaving healthy cells unharmed. This technology has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma.
Engineered T Cells are a rapidly growing field of biotechnology, with many companies developing new treatments and therapies. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in this field, developing innovative treatments and therapies for cancer and other diseases. Other companies such as Cellectis, Bluebird Bio, and Bellicum Pharmaceuticals are also making significant contributions to the field. Show Less Read more